As shown in Figure 2A, only the rHGFK1 and rEndo+rHGFK1 treatments significantly decreased the percentage of CD90+ sub-populations in ML-1 cells and HepG2 cells (reduced to 35% and 42%, and 26% and 46%, of that of the control value, respectively), indicating that rHGFK1 had a significant inhibitory effect on the self-renewal of CD90+ CSCs of HCC cells, while Endo did not. Here, THY1 is linked to hepatocellular carcinoma.